Plasma biomarkers can identify Alzheimer's pathology years before cognitive decline becomes clinically apparent, yet clinical assessment protocols lag far behind this detection capability. Digitized cognitive testing that targets vulnerable neural networks bridges this gap, enabling functional decline detection concurrent with biomarker identification—a prerequisite for meaningful early intervention.
An FDA advisory panel voted to recommend six of seven experimental peptides for pharmacy compounding despite the agency's own scientific review recommending against all of them. The decision relocates supply chains from gray-market importers to regulated pharmacies but does not constitute validation of efficacy or safety.
Longevity research has advanced substantially in laboratories, but regulatory and policy frameworks have not kept pace, creating a critical bottleneck between scientific discovery and patient access. The Alliance for Longevity Initiatives is working to integrate aging science into mainstream health policy, treating healthy longevity as a national priority rather than a niche scientific interest.
Serotonin Centers opened a Del Mar location offering hormone optimization, peptide therapy, IV therapy, hyperbaric oxygen therapy, and advanced diagnostics under physician oversight. This represents a commercial expansion of medically supervised wellness services in response to documented consumer demand for integrated longevity protocols.
NADclinic and the Geneva College of Longevity Science have established a clinical education partnership to standardize practitioner training in longevity and preventive medicine. The collaboration centers on structured postgraduate programs, including peptide therapeutics certification, designed to improve clinical outcomes through evidence-based practice and regulatory awareness.
Cold-induced sexual differentiation in Hydra oligactis produces distinct metabolic signatures of both reproductive maturation and aging, with taurine depletion emerging as a critical marker of cellular decline. Taurine supplementation partially restored stem cell populations and shifted reproduction from sexual to asexual, suggesting a metabolic lever for longevity intervention.
Medical breakthroughs often emerge from curiosity-driven observation rather than hypothesis-driven research, fundamentally shaping how we understand and treat disease. Understanding this pattern—that discovery precedes engineering—informs how we approach modern health optimization.
Age-related decline in the sirtuin AcSirt2 impairs mitochondrial quality control in honey bees, while restoring this protein activates a FOXO-dependent pathway that clears damaged mitochondria, reduces oxidative stress, and extends lifespan. This mechanism identifies a conserved axis for mitochondrial homeostasis relevant to aging across species.
Researchers developed plasma protein-based aging clocks that measure musculoskeletal aging acceleration independently of chronological age, with MSKAgeMortAccel predicting mortality and musculoskeletal disease risk substantially better than existing models. Environmental factors, genetic variants, and zinc status emerged as modifiable determinants of musculoskeletal aging rate, enabling targeted risk stratification and intervention.
The LATTICE trial found no cognitive benefit from lithium supplementation in Alzheimer's disease, challenging earlier observational evidence suggesting neuroprotective effects. This null result reshapes the evidence landscape for lithium as a preventive intervention and highlights the gap between population-level associations and clinical efficacy in neurodegenerative disease.
Rani Therapeutics partnered with PegBio to develop oral formulations of obesity and metabolic disease therapies using its RaniPill platform, addressing a critical barrier to long-term treatment adherence. The collaboration evaluates multiple drug candidates with different mechanisms of action, reflecting the field's shift beyond single-pathway GLP-1 therapies toward personalized metabolic intervention.
A 27-year-old New York City woman died following an intravenous NAD⁺ infusion administered by an unlicensed practitioner at an unregulated wellness clinic. The death highlights the distinction between evidence-supported NAD⁺ research—which shows promise in animal models but remains unconvincing in human studies—and the proliferation of unproven intravenous formulations marketed without scientific validation or medical oversight.
